Does chemosensitivity-assay-directed therapy have an influence on the prognosis of patients with malignant melanoma stage IV? A retrospective study of 14 patients with malignant melanoma stage IV

European Journal of Medical Research

Volumn 12, Issue 10, 2007, Pages 497-502

  Doerler, M ^a   Hyun, J ^b   Venten, I ^a   Potthoff, A ^a   Bartke, U ^a   Serova, K ^a   Hoextermann, S ^a   Altmeyer, P ^a   Brockmeyer, Norbert H ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; CISPLATIN; DOXORUBICIN; GEMCITABINE; LACTATE DEHYDROGENASE; PACLITAXEL; TEMOZOLOMIDE; TREOSULFAN; VINDESINE; VISCUM ALBUM EXTRACT;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; FISHER EXACT TEST; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LACTATE DEHYDROGENASE BLOOD LEVEL; LOG RANK TEST; MALE; MELANOMA; METASTASIS; OVERALL SURVIVAL; PROGNOSIS; RETROSPECTIVE STUDY; SEX RATIO; SURVIVAL RATE;

ADULT; AGED; DRUG THERAPY; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 36248991384     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Cummins DL, Cummins JM, Pantle H, Silverman MA, Leonard AL, Chanmugam A. Cutaneous malignant melanoma. Mayo Clin Proc 2006; 81: 500-507.
2. Hauschild A, Kleeberg UR. Adjuvant therapy of melanoma. From non-specific immune stimulants into the future. Hautarzt 2006; 57(9): 764-72.
3. Adnane L, Trail PA, Taylor I, Wilhelm SM. Sorafenib (BAY 43-9006, Nexavar), a dual action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 2005; 407: 597-612.
4. Flaherty KT. Chemotherapy and targeted therapy combinations in advanced melanoma. Clin Cancer Res 2006; 12: 2366s-2370s.
5. Food and Drug Administration Center for Drug Evaluation and Research: Oncologic Drugs Advisory Committee, Briefing Material: May 3, 2004 AM Session-Genasense. http://www.fda.gov/ohrms/dockets/ac/04/briefing/ 4037B1.02.FDA-Genasense.pdf
6. Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, Bröcker EB, Grabbe S, Rittgen W, Edler L, Sucker A, Zimpfer-Rechner C, Berger T, Kamarashev J, Burg G, Jonuleit H, Tüttenberg A Becker JC, Keikavoussi P, Kämpgen E, Schuler G; DC study group of the DeCOG. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006; 17: 563-70.
7. Ugurel S, Schadendorf D, Pfohler C, Neuber K, Thoelke A, Ulrich J, Hauschild A, Spieth K, Kaatz M, Rittgen W, Delorme S, Tilgen W, Reinhold U; Dermatologic Cooperative Oncology Group. In vitro Drug Sensitivity Predicts Response and Survival after Individualized Sensitivity-Directed Chemotherapy in Metastatic Melanoma: A Multicenter Phase II Trial of the Dermatologic Cooperative Oncology Group. Clin Cancer Res 2006; 12(18): 5454-63.
8. Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, Gleiberman I, Caruso PA, Ricks SH, Untch M et al. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 1995; 55: 5276-82.
9. Kurbacher CM, Cree IA. Chemosensitivity testing using microplate adenosine triphosphate-based luminescence measurements. Methods Mol Med 2005; 110: 101-20.
10. Garbe C, Eigentler TK. Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Research 2007; 17/2: 117-127.
11. Robinson WA, Mughal TI, Thomas MR, Johnson M, Spiegel RJ. Treatment of metastatic malignant melanoma with recombinant interferon alpha 2. Immunobiology 1986; 172: 275-282.
12. Miller RL, Steis RG, Clark JW, Smith JW 2nd, Crum E, Mc Knight JE, Hawkins MJ, Jones MJ, Longo DL, Urba WJ. Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanoma. Cancer Res 1989; 49: 1871-1876.
13. Eigentler TK, Carob UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomized clinical trials. Lancet Oncol 2003; 4: 748-759.
14. Middleton M, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Creno A, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher N. Randomized Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18: 158-166.
15. Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic melanoma: time for a change? Cancer 2007; 109 (3): 455-64.
16. Homsi J, Kashani-Sabet M, Messina JL, Daud A. Cutaneous melanoma: prognostic factors. Cancer Control 2005; 12(4): 223-9.
17. Vossaert KA, Silverman MK, Kopf AW, Bart RS, Rigel DS, Friedman RJ, Levenstein M. Influence of gender on survival in patients with stage I malignant melanoma. J Am Acad Dermatol 1992; 26 (3 pt 2): 429-440.
18. Balch CM. Cutaneous melanoma: prognosis and treatment results worldwide. Semin Surg Oncol 1992; 8: 400-414.
19. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-3648.
20. Kurbacher CM, Grecu OM, Stier U, Gilster TJ, Janat MM, Untch M, Konecny G, Bruckner HW, Cree IA. ATP chemosensitivity testing in ovarian and breast cancer: early clinical trials. Recent Results Cancer Res 2003; 161: 221-30.